Ys Biopharma Co Stock Performance
| YS Stock | 0.54 0.01 1.89% |
The firm owns a Beta (Systematic Risk) of -0.1643, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning YS Biopharma are expected to decrease at a much lower rate. During the bear market, YS Biopharma is likely to outperform the market. Even though it is essential to pay attention to YS Biopharma existing price patterns, it is always good to be careful when utilizing equity price patterns. Our approach towards determining any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. YS Biopharma exposes fifteen different technical indicators, which can help you to evaluate its performance. YS Biopharma has an expected return of -1.0%. Please make sure to check out YS Biopharma Co standard deviation, as well as the relationship between the treynor ratio and potential upside to decide if YS Biopharma performance from the past will be repeated at some future date.
YS Biopharma Performance
0 of 100
Over the last 90 days YS Biopharma Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | YS Biopharma Announces First Subject Enrollment in Pivotal Phase ... - Marketscreener.com | 09/26/2023 |
2 | Other | 10/26/2023 |
3 | Noble Capital Markets Initiates Coverage on YS Biopharma With ... - Marketscreener.com | 11/14/2023 |
| Begin Period Cash Flow | 271.1 M |
YS Biopharma |
YS Biopharma Relative Risk vs. Return Landscape
If you would invest 112.00 in YS Biopharma Co on September 7, 2023 and sell it today you would lose (58.00) from holding YS Biopharma Co or give up 51.79% of portfolio value over 90 days. YS Biopharma Co is generating negative expected returns and assumes 5.4995% volatility on return distribution over the 90 days horizon. Put differently, 48% of stocks are less risky than YS Biopharma on the basis of their historical return distribution, and some 99% of all equities are expected to be superior in generating returns on investments over the next 90 days. Expected Return |
| Risk |
YS Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for YS Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as YS Biopharma Co, and traders can use it to determine the average amount a YS Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1819
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | YS |
Estimated Market Risk
| 5.5 actual daily | 48 52% of assets are more volatile |
Expected Return
| -1.0 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average YS Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of YS Biopharma by adding YS Biopharma to a well-diversified portfolio.
YS Biopharma Fundamentals Growth
YS Biopharma Stock prices reflect investors' perceptions of the future prospects and financial health of YS Biopharma, and YS Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on YS Biopharma Stock performance.
| Return On Equity | -0.45 | ||||
| Profit Margin | (0.45) % | ||||
| Current Valuation | 480.42 M | ||||
| Shares Outstanding | 93.06 M | ||||
| Revenue | 687.2 M | ||||
| EBITDA | (76.82 M) | ||||
| Net Income | (145.48 M) | ||||
| Total Debt | 498.63 M | ||||
| Book Value Per Share | 7.10 X | ||||
| Cash Flow From Operations | (182.47 M) | ||||
| Earnings Per Share | (0.29) X | ||||
| Market Capitalization | 44.67 M | ||||
| Total Asset | 1.72 B | ||||
| Retained Earnings | (1.87 B) | ||||
| Working Capital | 377.22 M | ||||
About YS Biopharma Performance
To evaluate YS Biopharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when YS Biopharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare YS Biopharma Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand YS Biopharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents YS Biopharma's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for 2023 | ||
| Effect of Exchange Rate Changes on Cash | 21.3 M | 23 M | |
| Return on Average Assets | (0.27) | (0.29) | |
| Return on Average Equity | (28.59) | (29.34) | |
| Return on Invested Capital | (0.24) | (0.26) | |
| Return on Sales | (0.37) | (0.39) |
Things to note about YS Biopharma performance evaluation
Checking the ongoing alerts about YS Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for YS Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| YS Biopharma generated a negative expected return over the last 90 days | |
| YS Biopharma has high historical volatility and very poor performance | |
| YS Biopharma has some characteristics of a very speculative penny stock | |
| YS Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company generated the yearly revenue of 687.2 M. Annual Net Loss to common stockholders was (145.48 M) with gross profit of 0. | |
| YS Biopharma generates negative cash flow from operations | |
| Latest headline from news.google.com: Noble Capital Markets Initiates Coverage on YS Biopharma With ... - Marketscreener.com |
- Analyzing YS Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether YS Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining YS Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating YS Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of YS Biopharma's management team can help you assess the company's leadership.
- Pay attention to analyst opinions and ratings of YS Biopharma's stock. These opinions can provide insight into YS Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in YS Biopharma Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for YS Biopharma Stock analysis
When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 6.524 | Quarterly Revenue Growth (0.14) | Return On Equity (0.45) |
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.